Pacira Pharmaceuticals Inc (NASDAQ:PCRX) was the recipient of unusually large options trading activity on Wednesday. Stock investors acquired 1,729 call options on the company. This represents an increase of approximately 1,887% compared to the average daily volume of 87 call options.
Shares of Pacira Pharmaceuticals stock opened at $32.25 on Thursday. Pacira Pharmaceuticals has a 52 week low of $27.80 and a 52 week high of $52.47. The company has a market cap of $1,220.33, a price-to-earnings ratio of -29.59 and a beta of 1.95. The company has a quick ratio of 6.22, a current ratio of 6.96 and a debt-to-equity ratio of 0.99.
Pacira Pharmaceuticals (NASDAQ:PCRX) last released its earnings results on Wednesday, February 28th. The company reported $0.38 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.08) by $0.46. The company had revenue of $79.08 million during the quarter, compared to analysts’ expectations of $79.06 million. Pacira Pharmaceuticals had a negative net margin of 14.87% and a negative return on equity of 8.55%. The business’s revenue was up 8.5% on a year-over-year basis. During the same quarter last year, the business earned $0.09 EPS. equities research analysts expect that Pacira Pharmaceuticals will post -0.58 earnings per share for the current fiscal year.
Institutional investors and hedge funds have recently made changes to their positions in the company. First Republic Investment Management Inc. purchased a new position in shares of Pacira Pharmaceuticals in the 4th quarter valued at about $201,000. Bouchey Financial Group Ltd purchased a new position in shares of Pacira Pharmaceuticals in the 4th quarter valued at about $205,000. Twin Focus Capital Partners LLC purchased a new position in shares of Pacira Pharmaceuticals in the 4th quarter valued at about $206,000. Redmile Group LLC purchased a new position in shares of Pacira Pharmaceuticals in the 4th quarter valued at about $237,000. Finally, Fisher Asset Management LLC purchased a new position in shares of Pacira Pharmaceuticals in the 4th quarter valued at about $241,000.
A number of brokerages recently weighed in on PCRX. Mizuho decreased their price target on shares of Pacira Pharmaceuticals from $44.00 to $31.00 and set a “neutral” rating for the company in a research note on Wednesday. Seaport Global Securities reiterated a “buy” rating and set a $42.00 price target on shares of Pacira Pharmaceuticals in a research note on Tuesday. Zacks Investment Research upgraded shares of Pacira Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, March 6th. BMO Capital Markets decreased their price target on shares of Pacira Pharmaceuticals from $32.00 to $31.00 and set a “market perform” rating for the company in a research note on Thursday, March 1st. Finally, Royal Bank of Canada set a $44.00 price target on shares of Pacira Pharmaceuticals and gave the stock a “buy” rating in a research note on Thursday, March 1st. Three research analysts have rated the stock with a sell rating, twelve have given a hold rating and eight have given a buy rating to the stock. Pacira Pharmaceuticals currently has a consensus rating of “Hold” and a consensus price target of $44.06.
COPYRIGHT VIOLATION WARNING: This news story was originally published by Markets Daily and is owned by of Markets Daily. If you are viewing this news story on another website, it was illegally stolen and republished in violation of United States & international trademark and copyright law. The legal version of this news story can be viewed at https://www.themarketsdaily.com/2018/03/22/traders-buy-large-volume-of-call-options-on-pacira-pharmaceuticals-pcrx.html.
Pacira Pharmaceuticals Company Profile
Pacira Pharmaceuticals, Inc is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers.
Receive News & Ratings for Pacira Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.